New hope for BRCA-Linked breast cancer: targeted drug talazoparib under study
NCT ID NCT03990896
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing the drug talazoparib (Talzenna) in 30 people with metastatic breast cancer that has spread beyond the breast. The cancer must have a specific BRCA gene mutation found only in the tumor (not inherited). Talazoparib works by blocking proteins that help repair DNA in cancer cells, which may cause the cells to die. The study measures how long the cancer stays under control and whether tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Talazoparib (Talzenna), a PARP inhibitor drug
What this could lead to
If successful, this could provide a targeted treatment option for people with metastatic breast cancer who have BRCA mutations in their tumor cells, potentially slowing disease progression.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may not work for all patients, and side effects like fatigue or nausea are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital Cancer Center
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UCSF Medical Center-Mission Bay/Benioff Children's Hospital
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vanderbilt University
RECRUITINGNashville, Tennessee, 37232-6307, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact